<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24532969</article-id><article-id pub-id-type="pmc">3923615</article-id><article-id pub-id-type="doi">10.2147/COPD.S55419</article-id><article-id pub-id-type="publisher-id">copd-9-179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Siva</surname><given-names>Roshan</given-names></name><xref ref-type="aff" rid="af1-copd-9-179">1</xref></contrib><contrib contrib-type="author"><name><surname>Bafadhel</surname><given-names>Mona</given-names></name><xref ref-type="aff" rid="af2-copd-9-179">2</xref></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>William</given-names></name><xref ref-type="aff" rid="af3-copd-9-179">3</xref></contrib><contrib contrib-type="author"><name><surname>Brightling</surname><given-names>Christopher E</given-names></name><xref ref-type="aff" rid="af3-copd-9-179">3</xref></contrib><contrib contrib-type="author"><name><surname>Pavord</surname><given-names>Ian D</given-names></name><xref ref-type="aff" rid="af2-copd-9-179">2</xref><xref ref-type="corresp" rid="c1-copd-9-179"/></contrib></contrib-group><aff id="af1-copd-9-179"><label>1</label>Department of Respiratory Medicine, Croydon University Hospital, Croydon Health Services NHS Trust, London, UK</aff><aff id="af2-copd-9-179"><label>2</label>Department of Respiratory Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Oxford, UK</aff><aff id="af3-copd-9-179"><label>3</label>Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK</aff><author-notes><corresp id="c1-copd-9-179">Correspondence: Ian D Pavord, Department of Respiratory Medicine, NDM Research Building, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford OX3 7FZ, UK, Tel +44 1865 612897, Email <email>ian.pavord@ndm.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>07</day><month>2</month><year>2014</year></pub-date><volume>9</volume><fpage>179</fpage><lpage>186</lpage><permissions><copyright-statement>&#x000a9; 2014 Siva et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Rationale</title><p>Airway inflammation persists after smoking cessation in established chronic obstructive pulmonary disease (COPD), suggesting that other factors drive the airway inflammatory response.</p></sec><sec><title>Objectives</title><p>We tested the hypothesis that high levels of bacterial colonization are associated with increased levels of neutrophilic airway inflammation in stable COPD by examining the cross-sectional relationship between these measurements and by conducting a randomized, double-blind, placebo-controlled study of the effect of levofloxacin in patients with stable COPD.</p></sec><sec><title>Methods</title><p>Patients were randomized to receive either levofloxacin 500 mg daily or placebo for 7 days and underwent sputum induction for a differential cell count and quantitative bacterial analysis at baseline and at days 7, 14, and 28.</p></sec><sec><title>Results</title><p>Sputum percentage neutrophil count correlated with airway bacterial load at baseline (<italic>r</italic>=0.56; <italic>P</italic>=0.003). Levofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4&#x02013;25.7; <italic>P</italic>=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10<sup>6</sup> cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%&#x02013;51.3%; <italic>P</italic>=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7. Change in percentage neutrophil count correlated significantly with baseline airway bacterial load and change in airway bacterial load.</p></sec><sec><title>Conclusion</title><p>In stable COPD, levofloxacin treatment causes a short-term reduction in bacterial load. This is associated with a reduction in neutrophilic airway inflammation in patients with high bacterial loads. Further studies are required to investigate whether this effect is clinically advantageous.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>bacteria</kwd><kwd>antibiotics</kwd><kwd>sputum</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is a slowly progressive chronic inflammatory disease, affecting mainly the airways, that is characterized by an accelerated decline in lung function.<xref rid="b1-copd-9-179" ref-type="bibr">1</xref> The main etiological agent associated with developing COPD is cigarette smoke, and smoking cessation has been shown to slow this accelerated decline in lung function.<xref rid="b2-copd-9-179" ref-type="bibr">2</xref> However, the rate of decline of lung function is variable among patients, and other sources of local<xref rid="b3-copd-9-179" ref-type="bibr">3</xref>&#x02013;<xref rid="b5-copd-9-179" ref-type="bibr">5</xref> and systemic<xref rid="b3-copd-9-179" ref-type="bibr">3</xref>,<xref rid="b6-copd-9-179" ref-type="bibr">6</xref> inflammation may contribute. In keeping with this view, airway inflammation has been shown to persist after smoking cessation in patients with established COPD.<xref rid="b7-copd-9-179" ref-type="bibr">7</xref>,<xref rid="b8-copd-9-179" ref-type="bibr">8</xref></p><p>Neutrophilic airway inflammation has been shown to be associated with forced expiratory volume in 1 second (FEV<sub>1</sub>) in cross-sectional analysis<xref rid="b5-copd-9-179" ref-type="bibr">5</xref> and, longitudinally, with decline in FEV<sub>1</sub>,<xref rid="b7-copd-9-179" ref-type="bibr">7</xref> suggesting a role in the genesis of the small airway inflammation and fibrosis that leads to the progressive airflow obstruction seen in COPD.<xref rid="b9-copd-9-179" ref-type="bibr">9</xref> One potentially modifiable cause of neutrophilic airway inflammation is bacterial infection of the airway. The presence of potentially pathogenic microorganisms (PPMs) has been associated with higher levels of markers of neutrophilic airway inflammation during stable disease<xref rid="b10-copd-9-179" ref-type="bibr">10</xref> and at exacerbation.<xref rid="b11-copd-9-179" ref-type="bibr">11</xref>&#x02013;<xref rid="b13-copd-9-179" ref-type="bibr">13</xref> Moreover, uncontrolled studies have shown that reduction of bacterial load with antibiotic therapy is associated with resolution of neutrophilic airway inflammation in patients studied during an exacerbation<xref rid="b14-copd-9-179" ref-type="bibr">14</xref> with elevated total neutrophils in the presence of a PPM.<xref rid="b15-copd-9-179" ref-type="bibr">15</xref>,<xref rid="b16-copd-9-179" ref-type="bibr">16</xref> Less is known about the relationship between bacterial colonization of the airway and neutrophilic airway inflammation in stable COPD. We have tested the hypothesis that high levels of bacterial colonization are causally associated with increased levels of neutrophilic airway inflammation in stable COPD by examining the cross-sectional relationship between these measurements and by conducting a randomized, double-blind, placebo-controlled study of the effect of a 1 week course of levofloxacin on bacterial load and markers of neutrophilic airway inflammation in patients with stable-state COPD.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="subjects"><title>Participants</title><p>Participants with a physician diagnosis of COPD were recruited from Glenfield Hospital, Leicester, UK, between January 2003 and January 2004. All patients had fixed airway obstruction, with an FEV<sub>1</sub>/FVC ratio of &#x0003c;0.7 and an FEV<sub>1</sub> %predicted of &#x0003c;80%. The exclusion criteria were as follows: patients younger than 45 years; a clinical history of asthma or acute wheeze, breathlessness, or deterioration associated with allergens; or clinically important comorbidity such as heart failure, bronchiectasis, or lung cancer. Any evidence of airway reversibility following 400 micrograms of inhaled Salbutamol (&#x0003e;15% or &#x0003e;200 mL) was also an exclusion criterion. Patients receiving regular antibiotic therapy, elevated immunoglobulin E levels (&#x0003e;500 U/L), and PiZZ homozygosis for alpha-1 antitrypsin were also excluded. At enrollment, patients were 6 weeks free of an exacerbation. The study was approved by the Leicestershire and Rutland research ethics committee, and all subjects gave written informed consent. The clinical trial was not registered, as it was carried out before the mandatory requirements for registration of clinical trials.</p></sec><sec><title>Measurements</title><p>The following baseline characteristics were recorded: age, sex, body mass index, serum immunoglobulin E, alpha-1-antitrypsin level, smoking history, and comorbid history. All patients underwent a chest X-ray and full pulmonary function testing. Spirometry was always carried out in the morning and performed by taking the best of three readings, using Vitalograph&#x000ae; (Lenexa, KS, USA), before and 15 minutes after inhalation of salbutamol 400 &#x003bc;g via a large-volume spacer device. Gas transfer and total lung volumes were measured using the single-breath-hold carbon monoxide technique and helium dilution technique, respectively. At each visit, patients underwent spirometry, sputum induction according to a standard protocol,<xref rid="b17-copd-9-179" ref-type="bibr">17</xref>,<xref rid="b18-copd-9-179" ref-type="bibr">18</xref> diary card review, and assessment of symptoms using visual analog scales on which patients marked 3 lines, each measuring 100 mm, which represented the symptoms of breathlessness, cough, and sputum production.<xref rid="b19-copd-9-179" ref-type="bibr">19</xref> Sputum was processed according to a standard protocol<xref rid="b18-copd-9-179" ref-type="bibr">18</xref> and analyzed for differential cell count by counting more than 400 nonsquamous cells on a Romanowski (0.5g Eosin, 1.5g Azure-B-thiocyanate, 10nM HEPES buffer pH7.2, dimethyl sulfoxide) stained cytospin. A quantitative bacterial count was performed by using homogenized sputum to create a dilutional series, which was then pipetted onto media plates and incubated for 24 hours.<xref rid="b20-copd-9-179" ref-type="bibr">20</xref> Bacterial colonies were identified and counted to calculate airway bacterial load, expressed as colony forming units (CFU)/mL sputum.<xref rid="b21-copd-9-179" ref-type="bibr">21</xref> A potential PPM was defined as the presence of <italic>Haemophilus influenzae</italic>, <italic>Streptococcus pneumoniae</italic>, <italic>Moraxella catarrhalis</italic>, <italic>Staphylococcus aureus</italic>, or <italic>Pseudomonas</italic> species on routine sputum culture.<xref rid="b20-copd-9-179" ref-type="bibr">20</xref> Bacterial load higher than &#x000d7;10<sup>6</sup> cfu/mL was chosen a priori for subgroup analysis, as this level has been shown to be associated with increased neutrophilic airway inflammation.<xref rid="b22-copd-9-179" ref-type="bibr">22</xref> Sputum supernatants were frozen at &#x02212;80&#x000b0;C for measurement of interleukin-8 (IL-8) concentrations by enzyme-linked immunosorbent assay, using a commercially available kit (R&#x00026;D Systems Europe, Abingdon, UK). The limit of detection of IL-8 was 1.5 &#x003bc;g, and the between-assay and within-assay variability was between 5% and 10%.</p></sec><sec><title>Protocol</title><p>At the baseline visit, patients were randomized to receive either a 7-day course of levofloxacin 500 mg once daily or matched placebo in a randomized, double-blind control trial. The randomization process was carried out by Royal Hallamshire Hospital, which supplied the medication. The patients were followed up in the morning, at least 2 hours after taking their study medication, on days 7, 14, and 28, and measurements were repeated as stated earlier. Patients were asked to complete symptom diary score cards from the baseline visit to day 28. The study consort diagram is shown in <xref ref-type="fig" rid="f1-copd-9-179">Figure 1</xref>.</p></sec><sec sec-type="methods"><title>Analysis</title><p>The primary endpoints were change in sputum percentage neutrophil count, change in sputum IL-8 concentration, and the relationship between airway bacterial load and sputum percentage neutrophil count. Secondary endpoints were change in sputum total neutrophil count, symptoms, and postbronchodilator FEV<sub>1</sub>. The demographics of the two groups were compared using simple descriptive statistics. Changes in percentage neutrophil count, total neutrophil count, bacterial load, and IL-8 between each group were compared using unpaired Student&#x02019;s <italic>t</italic>-tests. The relationship between change in percentage neutrophil count and baseline bacterial load, as well as change in percentage neutrophil count and change in bacterial load, were analyzed using Spearman&#x02019;s rank correlation. The study was powered to have a greater than 80% chance of detecting a 20% difference in the percentage neutrophil count or a 2-fold difference in IL-8 with levofloxacin compared with placebo at the 5% significance level. All data were analyzed with SPSS for Windows (version 16.0; IBM Corporation, Armonk, NY, USA). All data were analyzed with intention to treat; missing data were assigned using measurements extrapolated from the last available visit.</p></sec></sec><sec sec-type="results"><title>Results</title><p>There were 27 patients randomized to receive levofloxacin (n=14) or placebo (n=13). Subjects were well matched at baseline (<xref ref-type="table" rid="t1-copd-9-179">Table 1</xref>). Two patients in the levofloxacin group withdrew from the study before day 7 because of Achilles tendonitis, confirmed on ultrasound scanning. At baseline, 6 patients had a PPM detected, and there was a correlation between the sputum percentage neutrophil count and log airway bacterial load (<italic>r</italic>=0.56; <italic>P</italic>=0.003; <xref ref-type="fig" rid="f2-copd-9-179">Figure 2</xref>). At day 7, the bacterial count increased from 1.1 &#x000d7; 10<sup>6</sup> cfu/mL to 1.5 &#x000d7; 10<sup>6</sup> cfu/mL in placebo and decreased from 0.7 &#x000d7; 10<sup>6</sup> cfu/mL to 0.2 &#x000d7; 10<sup>6</sup> cfu/mL with levofloxacin therapy. There was a 4.9-fold (95% confidence interval [CI], 1.4&#x02013;25.7; <italic>P</italic>=0.02) difference in the change in bacterial load between groups. There was no effect of levofloxacin at any point on any markers of neutrophilic airway inflammation (<xref ref-type="table" rid="t2-copd-9-179">Table 2</xref>). By day 7 there was a 1.3% reduction (95% CI, &#x02212;11.7% to 14.3%) in percentage neutrophil count with placebo and a 12% reduction (95% CI, &#x02212;5.9% to 30.1%) in percentage neutrophil count with levofloxacin (mean difference, 10.8%; 95% CI, &#x02212;9.7% to 31.2%; <italic>P</italic>=0.29). In patients with a baseline bacterial load higher than &#x000d7;10<sup>6</sup> cfu/mL, levofloxacin treatment was associated with a greater reduction in the percentage neutrophil count compared with placebo (mean difference, 26.5%; 95% CI, 1.8%&#x02013;51.3%; <italic>P</italic>=0.04; <xref ref-type="fig" rid="f3-copd-9-179">Figure 3</xref>) and a 46.8 ng/mL (95% CI, &#x02212;11.2 to 104.8 ng/mL; <italic>P</italic>=0.11) reduction in sputum IL-8 concentration. There was no evidence of a treatment effect at any other time (<xref ref-type="table" rid="t2-copd-9-179">Table 2</xref>). When sputum culture at baseline revealed the presence of a PPM, the reduction in percentage neutrophil count after levofloxacin at day 7 was 45.0% compared with 2.6% when there was nonsignificant growth (mean difference, 42.3%; 95% CI, 15.5%&#x02013;69.0%; <italic>P</italic>=0.006).</p><p>There was a significant correlation between change in percentage neutrophil count and baseline bacterial load after levofloxacin treatment (<italic>r</italic>=&#x02212;0.78; <italic>P</italic>=0.003) and between change in percentage neutrophil count and change in bacterial load (<italic>r</italic>=0.85; <italic>P</italic>=0.001). No such relationships were seen after placebo (<xref ref-type="fig" rid="f4-copd-9-179">Figure 4</xref>). There was no difference between the groups in change in postbronchodilator FEV<sub>1</sub> (mean difference, 28 mL; 95% CI, &#x02212;70 to 127 mL; <italic>P</italic>=0.56) or visual analog score from baseline to day 7 (mean difference, 2.6 mm; 95% CI, &#x02212;12.7 to 17.3 mm; <italic>P</italic>=0.71) or at any other time.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>We have shown a strong correlation between sputum percentage neutrophil count and baseline airway bacterial load and evidence that a reduction in bacterial load is associated with a reduction in neutrophilic airway inflammation in patients with high airway bacterial loads. This effect was only evident at day 7. There were correlations between change in percentage neutrophil count and baseline bacterial load and change in percentage neutrophil count and change in bacterial load. These effects were not associated with improvements in symptoms or FEV<sub>1</sub>.</p><p>Our findings are consistent with previous studies showing an increase in markers of neutrophilic airway inflammation associated with airway bacterial loads of more than 10<sup>6</sup> cfu/mL,<xref rid="b22-copd-9-179" ref-type="bibr">22</xref>,<xref rid="b23-copd-9-179" ref-type="bibr">23</xref> and with work showing that levels of neutrophilic airway inflammation are only suppressed for a short period after a course of antibiotics in patients with COPD.<xref rid="b14-copd-9-179" ref-type="bibr">14</xref> Our findings in stable COPD are consistent with an earlier uncontrolled trial in patients with stable bronchiectasis, in which there was evidence of reduction of neutrophil elastase concentration after treatment with amoxicillin.<xref rid="b24-copd-9-179" ref-type="bibr">24</xref> The similar time course of the effect of levofloxacin on bacterial load and sputum neutrophils and the correlation between change in sputum neutrophils and baseline bacterial load and change in bacterial load supports a causal link between airway bacterial colonization and neutrophilic airway inflammation. These findings are important, as they represent the first demonstration in a placebo-controlled trial that antibiotic therapy is capable of modulating neutrophilic airway inflammation in stable COPD.</p><p>We did not see any obvious clinical benefit with levofloxacin therapy during the study, although our study was not designed to show this. The long-term consequences of the effect of levofloxacin on neutrophilic airway inflammation and important clinical outcomes such as decline in lung function, quality of life, and symptoms remain unclear. However, a relationship between neutrophilic airway inflammation, decline in FEV<sub>1</sub>, and airway bacterial load is supported by a study that showed that an increase in bacterial load over the course of 12 months was related to a greater decline in FEV<sub>1</sub>.<xref rid="b4-copd-9-179" ref-type="bibr">4</xref> Higher levels of sputum IL-8 and a change in colonizing bacterial type were also associated with a greater decline in FEV<sub>1</sub>. These findings raise the possibility that reduction of airway bacterial load and neutrophilic airway inflammation with antibiotic therapy might be associated with a reduction in disease progression, including exacerbations.</p><p>Our study was not designed to show whether the effects of levofloxacin were related to infection with a PPM. PPMs tended to be present in high concentrations, and reduction in sputum neutrophils with levofloxacin was particularly marked in these patients, raising the possibility that the effect of levofloxacin was a result of a reduction in PPMs only. However, further, larger studies are needed to investigate this.</p><p>The use of antibiotics in the treatment of exacerbations of COPD, and particularly treatment of colonized patients who are clinically stable, remains controversial.<xref rid="b25-copd-9-179" ref-type="bibr">25</xref>,<xref rid="b26-copd-9-179" ref-type="bibr">26</xref> We chose to use levofloxacin because it has a broad spectrum of activity against common respiratory pathogens, it is given only once daily, it can be given to patients who are allergic to penicillin, and it is less likely to cause antibiotic resistance.<xref rid="b27-copd-9-179" ref-type="bibr">27</xref> Any potential benefits achieved by the increased use of antibiotics would have to be balanced against growing levels of bacterial antibiotic resistance and potential adverse effects, such as Achilles tendonitis and <italic>Clostridium difficile</italic> diarrhea, which may potentiate the considerable morbidity that already exists among these patients. The prophylactic use of antibiotics in COPD may be useful in a subgroup of patients<xref rid="b25-copd-9-179" ref-type="bibr">25</xref> with features of purulent sputum production or the chronic bronchitic phenotype. The mechanism by which levofloxacin may exert transitory reduction of bacterial load and neutrophil counts is not well studied. Observations from studies performed using macrolide therapy have demonstrated inhibition of neutrophil influx and stimulatory cytokine activity,<xref rid="b28-copd-9-179" ref-type="bibr">28</xref>,<xref rid="b29-copd-9-179" ref-type="bibr">29</xref> but whether this is a specific immune modulatory class effect remains to be established. In our study, the most benefit occurred in patients with PPM or elevated bacterial loads. This suggests that the antibactericidal properties of levofloxacin are able to exhibit a greater effect in a subgroup with the greatest inflammatory activity. Further evidence to support this includes studies that have shown equivalence of clinical success when different antibiotics are compared after treatment of an exacerbation of COPD.<xref rid="b30-copd-9-179" ref-type="bibr">30</xref>,<xref rid="b31-copd-9-179" ref-type="bibr">31</xref> Our findings provide further basis for trials investigating the effect of long-term antibiotic therapy on clinically relevant outcomes in a select group of patients with stable COPD.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the volunteers for taking part in the study and the following individuals for patient characterization; Mrs B Hargadon, Mrs S McKenna, Mrs M Shelley, and Mr S Winpress.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>CEB and IDP have received grant support from AstraZeneca, Roche, and GlaxoSmithKline. The authors have no other conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-9-179"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><issue>6</issue><fpage>532</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">17507545</pub-id></element-citation></ref><ref id="b2-copd-9-179"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>C</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name></person-group><article-title>The natural history of chronic airflow obstruction</article-title><source>Br Med J</source><year>1977</year><volume>1</volume><issue>6077</issue><fpage>1645</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">871704</pub-id></element-citation></ref><ref id="b3-copd-9-179"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Patel</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Airway and systemic inflammation and decline in lung function in patients with COPD</article-title><source>Chest</source><year>2005</year><volume>128</volume><issue>4</issue><fpage>1995</fpage><lpage>2004</lpage><pub-id pub-id-type="pmid">16236847</pub-id></element-citation></ref><ref id="b4-copd-9-179"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>TM</given-names></name><name><surname>Patel</surname><given-names>IS</given-names></name><name><surname>Wilks</surname><given-names>M</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Airway bacterial load and FEV<sub>1</sub> decline in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><issue>8</issue><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">12684248</pub-id></element-citation></ref><ref id="b5-copd-9-179"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>RA</given-names></name><name><surname>Peebles</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>10</issue><fpage>837</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">15454648</pub-id></element-citation></ref><ref id="b6-copd-9-179"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>J</given-names></name></person-group><article-title>Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients</article-title><source>Chest</source><year>2003</year><volume>123</volume><issue>2</issue><fpage>596</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">12576384</pub-id></element-citation></ref><ref id="b7-copd-9-179"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x00103;nescu</surname><given-names>D</given-names></name><name><surname>Sanna</surname><given-names>A</given-names></name><name><surname>Veriter</surname><given-names>C</given-names></name><etal/></person-group><article-title>Airways obstruction, chronic expectoration, and rapid decline of FEV<sub>1</sub> in smokers are associated with increased levels of sputum neutrophils</article-title><source>Thorax</source><year>1996</year><volume>51</volume><issue>3</issue><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">8779129</pub-id></element-citation></ref><ref id="b8-copd-9-179"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turato</surname><given-names>G</given-names></name><name><surname>Zuin</surname><given-names>R</given-names></name><name><surname>Miniati</surname><given-names>M</given-names></name><etal/></person-group><article-title>Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>1</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12091179</pub-id></element-citation></ref><ref id="b9-copd-9-179"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Utokaparch</surname><given-names>S</given-names></name><etal/></person-group><article-title>The nature of small-airway obstruction in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>26</issue><fpage>2645</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">15215480</pub-id></element-citation></ref><ref id="b10-copd-9-179"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Khair</surname><given-names>OA</given-names></name><name><surname>Honeybourne</surname><given-names>D</given-names></name></person-group><article-title>Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><issue>5</issue><fpage>685</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">15176680</pub-id></element-citation></ref><ref id="b11-copd-9-179"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M</given-names></name><name><surname>McKenna</surname><given-names>S</given-names></name><name><surname>Terry</surname><given-names>S</given-names></name><etal/></person-group><article-title>Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers</article-title><source>Am J Respir Crit Care Med</source><year>2011</year><volume>184</volume><issue>6</issue><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">21680942</pub-id></element-citation></ref><ref id="b12-copd-9-179"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>IS</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Wilks</surname><given-names>M</given-names></name><name><surname>Lloyd-Owen</surname><given-names>SJ</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations</article-title><source>Thorax</source><year>2002</year><volume>57</volume><issue>9</issue><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">12200518</pub-id></element-citation></ref><ref id="b13-copd-9-179"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>A</given-names></name><name><surname>Bellettato</surname><given-names>CM</given-names></name><name><surname>Braccioni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><issue>10</issue><fpage>1114</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">16484677</pub-id></element-citation></ref><ref id="b14-copd-9-179"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Gompertz</surname><given-names>S</given-names></name><name><surname>Bayley</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis</article-title><source>Thorax</source><year>2003</year><volume>58</volume><issue>8</issue><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">12885984</pub-id></element-citation></ref><ref id="b15-copd-9-179"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>AT</given-names></name><name><surname>Campbell</surname><given-names>EJ</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Bayley</surname><given-names>DL</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis</article-title><source>Am J Med</source><year>2000</year><volume>109</volume><issue>4</issue><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">10996579</pub-id></element-citation></ref><ref id="b16-copd-9-179"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>A</given-names></name><name><surname>Mons&#x000f3;</surname><given-names>E</given-names></name><name><surname>Garcia-Nu&#x000f1;ez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Variability and effects of bronchial colonisation in patients with moderate COPD</article-title><source>Eur Respir J</source><year>2010</year><volume>35</volume><issue>2</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">19643939</pub-id></element-citation></ref><ref id="b17-copd-9-179"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Hargreave</surname><given-names>FE</given-names></name><etal/></person-group><article-title>Clinical applications of assessment of airway inflammation using induced sputum</article-title><source>Eur Respir J Suppl</source><year>2002</year><volume>37</volume><fpage>40s</fpage><lpage>43s</lpage><pub-id pub-id-type="pmid">12361362</pub-id></element-citation></ref><ref id="b18-copd-9-179"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzichini</surname><given-names>E</given-names></name><name><surname>Pizzichini</surname><given-names>MM</given-names></name><name><surname>Efthimiadis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><issue>2 Pt 1</issue><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">8756799</pub-id></element-citation></ref><ref id="b19-copd-9-179"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Monterio</surname><given-names>W</given-names></name><name><surname>Green</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability</article-title><source>Respir Med</source><year>2001</year><volume>95</volume><issue>12</issue><fpage>999</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">11778799</pub-id></element-citation></ref><ref id="b20-copd-9-179"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Health Protection Agency</collab></person-group><article-title>Investigation of bronchoalveolar lavage, sputum and associated specimens</article-title><source>National Standard Method BSOP 57 Issue 2.3||</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http//www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317132860548">http//www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317132860548</ext-link></comment><date-in-citation>Accessed on November 12, 2013</date-in-citation></element-citation></ref><ref id="b21-copd-9-179"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pye</surname><given-names>A</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name></person-group><article-title>Simple method for quantifying viable bacterial numbers in sputum</article-title><source>J Clin Pathol</source><year>1995</year><volume>48</volume><issue>8</issue><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">7560197</pub-id></element-citation></ref><ref id="b22-copd-9-179"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>C</given-names></name><name><surname>Pye</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name></person-group><article-title>Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD</article-title><source>Chest</source><year>2000</year><volume>117</volume><issue>6</issue><fpage>1638</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">10858396</pub-id></element-citation></ref><ref id="b23-copd-9-179"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Campbell</surname><given-names>EJ</given-names></name></person-group><article-title>Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency</article-title><source>Chest</source><year>2000</year><volume>117</volume><issue>5 Suppl 1</issue><fpage>291S</fpage><lpage>293S</lpage><pub-id pub-id-type="pmid">10843958</pub-id></element-citation></ref><ref id="b24-copd-9-179"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Morrison</surname><given-names>HM</given-names></name></person-group><article-title>Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state</article-title><source>Thorax</source><year>1984</year><volume>39</volume><issue>6</issue><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">6611601</pub-id></element-citation></ref><ref id="b25-copd-9-179"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Theron</surname><given-names>MS</given-names></name><etal/><collab>PULSE Study group</collab></person-group><article-title>Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial</article-title><source>Respir Res</source><year>2010</year><volume>11</volume><fpage>10</fpage><pub-id pub-id-type="pmid">20109213</pub-id></element-citation></ref><ref id="b26-copd-9-179"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>RK</given-names></name><name><surname>Connett</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>WC</given-names></name><etal/><collab>COPD Clinical Research Network</collab></person-group><article-title>Azithromycin for prevention of exacerbations of COPD</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>8</issue><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">21864166</pub-id></element-citation></ref><ref id="b27-copd-9-179"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lode</surname><given-names>H</given-names></name><name><surname>Allewelt</surname><given-names>M</given-names></name></person-group><article-title>Role of newer fluoroquinolones in lower respiratory tract infections</article-title><source>J Antimicrob Chemother</source><year>2002</year><volume>49</volume><issue>5</issue><fpage>709</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">12003962</pub-id></element-citation></ref><ref id="b28-copd-9-179"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Desaki</surname><given-names>M</given-names></name><name><surname>Ohtoshi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><issue>1</issue><fpage>266</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">9230759</pub-id></element-citation></ref><ref id="b29-copd-9-179"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadir</surname><given-names>T</given-names></name><name><surname>Izzetin</surname><given-names>FV</given-names></name><name><surname>Cevikbas&#x0015f;</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>CB</given-names></name><name><surname>Clark</surname><given-names>P</given-names></name></person-group><article-title>In vitro effects of clarithromycin on human polymorphonuclear leukocyte functions</article-title><source>Chemotherapy</source><year>2000</year><volume>46</volume><issue>3</issue><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">10765036</pub-id></element-citation></ref><ref id="b30-copd-9-179"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Allegra</surname><given-names>L</given-names></name><name><surname>Huchon</surname><given-names>G</given-names></name><etal/><collab>MOSAIC Study Group</collab></person-group><article-title>Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis</article-title><source>Chest</source><year>2004</year><volume>125</volume><issue>3</issue><fpage>953</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">15006954</pub-id></element-citation></ref><ref id="b31-copd-9-179"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><etal/></person-group><article-title>Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results</article-title><source>Eur Respir J</source><year>2012</year><volume>40</volume><issue>1</issue><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22135277</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-9-179" position="float"><label>Figure 1</label><caption><p>Assessments at each visit: pre- and postbronchodilator spirometry, sputum induction, and symptoms.</p></caption><graphic xlink:href="copd-9-179Fig1"/></fig><fig id="f2-copd-9-179" position="float"><label>Figure 2</label><caption><p>Relationship between airway bacterial load and percentage neutrophil count at baseline.</p><p><bold>Notes:</bold>
<italic>r</italic>=0.56; <italic>P</italic>=0.003.</p><p><bold>Abbreviations:</bold> O, nonsignificant growth; X, potentially pathogenic microorganisms.</p></caption><graphic xlink:href="copd-9-179Fig2"/></fig><fig id="f3-copd-9-179" position="float"><label>Figure 3</label><caption><p>Change in percentage neutrophil count in patients with airway bacterial load of more than 10<sup>6</sup> cfu/mL.</p><p><bold>Notes:</bold> Data presented as mean (standard error of the mean). Open circles represent placebo, closed circles represent levofloxacin.</p><p><bold>Abbreviation:</bold> SEM, standard error of the mean.</p></caption><graphic xlink:href="copd-9-179Fig3"/></fig><fig id="f4-copd-9-179" position="float"><label>Figure 4</label><caption><p>Mean change in percentage neutrophil count after (<bold>A</bold>) placebo and (<bold>B</bold>) levofloxacin, according to log baseline airway bacterial load.</p><p><bold>Abbreviations:</bold> O, nonsignificant growth; X, potentially pathogenic microorganism.</p></caption><graphic xlink:href="copd-9-179Fig4"/></fig><table-wrap id="t1-copd-9-179" position="float"><label>Table 1</label><caption><p>Patient demographics at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Placebo (n=13)</th><th align="left" valign="top" rowspan="1" colspan="1">Levofloxacin (n=14)</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (range)</td><td align="left" valign="top" rowspan="1" colspan="1">68 (45&#x02013;80)</td><td align="left" valign="top" rowspan="1" colspan="1">65 (52&#x02013;74)</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, males</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking status (current:ex)</td><td align="left" valign="top" rowspan="1" colspan="1">3:10</td><td align="left" valign="top" rowspan="1" colspan="1">7:7</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking pack years</td><td align="left" valign="top" rowspan="1" colspan="1">49.0 (29.7)</td><td align="left" valign="top" rowspan="1" colspan="1">49.0 (29.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proportion receiving inhaled corticosteroids</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">85%</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Inhaled corticosteroid dosage, &#x003bc;g<xref ref-type="table-fn" rid="tfn3-copd-9-179">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">1,600 (800&#x02013;2,000)</td><td align="left" valign="top" rowspan="1" colspan="1">1,600 (800&#x02013;2,000)</td><td align="left" valign="top" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/L</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC/L</td><td align="left" valign="top" rowspan="1" colspan="1">2.5 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2.3 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postbronchodilator FEV<sub>1</sub>/L</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postbronchodilator % predicted FEV<sub>1</sub></td><td align="left" valign="top" rowspan="1" colspan="1">43.8 (13.7)</td><td align="left" valign="top" rowspan="1" colspan="1">48.0 (16.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total lung capacity (% predicted)</td><td align="left" valign="top" rowspan="1" colspan="1">98.0 (18.7)</td><td align="left" valign="top" rowspan="1" colspan="1">97.7 (15.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Residual volume (% predicted)</td><td align="left" valign="top" rowspan="1" colspan="1">126.9 (60.4)</td><td align="left" valign="top" rowspan="1" colspan="1">133.8 (45.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diffusion capacity corrected for alveolar volume, (% predicted)</td><td align="left" valign="top" rowspan="1" colspan="1">66.0 (26.5)</td><td align="left" valign="top" rowspan="1" colspan="1">74.1 (18.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup></td><td align="left" valign="top" rowspan="1" colspan="1">25.7 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">24.4 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sputum total cell count (&#x000d7;10<sup>6</sup>/g)</td><td align="left" valign="top" rowspan="1" colspan="1">2.62 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sputum neutrophil count (%)</td><td align="left" valign="top" rowspan="1" colspan="1">66.2 (19.8)</td><td align="left" valign="top" rowspan="1" colspan="1">70.4 (21.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Airway bacterial load (&#x000d7;10<sup>6</sup> cfu/mL<xref ref-type="table-fn" rid="tfn2-copd-9-179">*</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proportion with airway bacterial load &#x0003e; &#x000d7;10<sup>6</sup> colonies, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (46%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (43%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-9-179"><p><bold>Notes:</bold> Mean (standard deviation) unless stated.</p></fn><fn id="tfn2-copd-9-179"><label>*</label><p>Geometric mean and log standard deviation</p></fn><fn id="tfn3-copd-9-179"><label>&#x02020;</label><p>beclomethasone dipropionate equivalent.</p></fn><fn id="tfn4-copd-9-179"><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-9-179" position="float"><label>Table 2</label><caption><p>Airway inflammation in levofloxacin and placebo groups over time series</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Treatment</th><th align="left" valign="top" rowspan="1" colspan="1">Baseline</th><th align="left" valign="top" rowspan="1" colspan="1">Day 7</th><th align="left" valign="top" rowspan="1" colspan="1">Day 14</th><th align="left" valign="top" rowspan="1" colspan="1">Day 28</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Total sputum cell count (&#x000d7;10<sup>6</sup>/g)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.3&#x02013;3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (0.9&#x02013;3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.0&#x02013;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (1.5&#x02013;3.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Levofloxacin</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (1.8&#x02013;4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.1&#x02013;3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (0.9&#x02013;5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (1.7&#x02013;5.2)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Neutrophil count (%)<xref ref-type="table-fn" rid="tfn6-copd-9-179">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">66.2 (19.8)</td><td align="left" valign="top" rowspan="1" colspan="1">64.9 (17.7)</td><td align="left" valign="top" rowspan="1" colspan="1">58.7 (20.9)</td><td align="left" valign="top" rowspan="1" colspan="1">59.1 (19.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Levofloxacin</td><td align="left" valign="top" rowspan="1" colspan="1">70.4 (21.4)</td><td align="left" valign="top" rowspan="1" colspan="1">58.2 (16.7)</td><td align="left" valign="top" rowspan="1" colspan="1">68.9 (16.4)</td><td align="left" valign="top" rowspan="1" colspan="1">70.1 (15.6)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Total neutrophil count (&#x000d7;10<sup>6</sup>/g)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.8&#x02013;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.5&#x02013;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.5&#x02013;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.7&#x02013;2.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Levofloxacin</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.1&#x02013;4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.4&#x02013;2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.4&#x02013;3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (0.9&#x02013;3.1)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Interleukin-8 (ng/mL)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">81.9 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">113.6 (82.3)</td><td align="left" valign="top" rowspan="1" colspan="1">120.8 (62.1)</td><td align="left" valign="top" rowspan="1" colspan="1">95.4 (75.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Levofloxacin</td><td align="left" valign="top" rowspan="1" colspan="1">95.1 (67.7)</td><td align="left" valign="top" rowspan="1" colspan="1">85.0 (56.3)</td><td align="left" valign="top" rowspan="1" colspan="1">124.8 (69.7)</td><td align="left" valign="top" rowspan="1" colspan="1">91.7 (74.5)</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Log bacterial load (cfu/mL<sup>&#x02212;1</sup>)<xref ref-type="table-fn" rid="tfn7-copd-9-179">&#x02020;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">6.05 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6.18 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">6.28 (0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">6.15 (0.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Levofloxacin</td><td align="left" valign="top" rowspan="1" colspan="1">5.87 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">5.33 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">5.86 (0.1)</td><td align="left" valign="top" rowspan="1" colspan="1">5.69 (0.2)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-copd-9-179"><p><bold>Notes:</bold> Data are presented as geometric mean (95% confidence interval) unless stated.</p></fn><fn id="tfn6-copd-9-179"><label>*</label><p>Mean (standard deviation)</p></fn><fn id="tfn7-copd-9-179"><label>&#x02020;</label><p>geometric mean (standard deviation).</p></fn></table-wrap-foot></table-wrap></floats-group></article>